IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

DSM Reports Steady Growth, Seeks Deal in Pharmaceuticals

3:01 AM MDT | August 2, 2011 | Alex Scott

DSM has reported Ebitda for the second quarter of the year up 2% to €339 million ($482 million) on sales up 7% to €2.3 billion. Strong life sciences results were driven by robust growth in the group’s nutrition and materials businesses. The strong U.S. dollar negatively impacted the group overall, the company says.   The performance of the pharmaceuticals manufacturing business “remains below acceptable levels,” however, Sijbesma says. The pharma business recorded second quarter sales down 9% to €178 million. “We know...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa